Search
The research focused on sclerosing stromal tumor, a rare, benign ovarian tumor that is not cancer but can be misdiagnosed as cancer.
A study led by researchers at Memorial Sloan Kettering and New York University has shown that TET2 loss enhances the function of blood stem cells, causing them to renew themselves more efficiently than normal blood stem cells.
In 2023, the MSK Giving community raised a record-breaking $1 billion — 100% of which will support our mission of ending cancer for life.
A large study that analyzed nearly 120,000 cells in a developing mouse embryo is full of surprises.
Take a look back at some of the biggest science stories from this past year.
On November 3, 2021, a panel of MSK doctors joined The Abyssinian Baptist Church for an educational webinar about COVID-19 vaccination.
Discover where three recent Gerstner Sloan Kettering graduates are now and learn about the research they’re pursuing.
Memorial Sloan Kettering’s suburban presence is expanding with its newest and largest state-of-the-art facility set to welcome patients on October 6 in West Harrison, New York.
Experiments with zebrafish and human pluripotent stem cells reveal the necessary ingredients, besides genetic mutations, that fuel the development of melanoma.